Non-fatal stroke

Disease

1 paper1 finding

Associations

Oral incretin-based therapies

downin humans1RR 0.88

1 study

Oral incretin-based therapies lower the risk of non-fatal stroke in humans (RR 0.88, 95% CI 0.79–0.99).
“oral incretin therapies were associated with a modest but statistically significant reduction in the risk of non-fatal stroke (RR: 0.88; 95% CI: 0.79–0.99)”
Reviewtype 2 diabetesn = 62,821
Cardiovascular Outcomes of Oral Incretin-Based Therapies in Type 2 Diabetes: A Systematic Review and Meta-Analysis of 62,821 Patients
AHA Scientific Sessions 2025 abstract3 Nov 2025

Latest

16 in 12 months

Frontiers in Cardiovascular Medicine8 h

Cardiovascular outcomes of oral incretin-based drugs in type 2 diabetes: a GRADE-assessed meta-analysis of 67,679 patients

Meta-analysis of randomised trialsType 2 diabetes

Paper

International Journal of Cardiology20 h

Prognostic associations of left atrial strain with major adverse cardiovascular events and atrial fibrillation: Data from the Akershus cardiac examination (ACE) 1950 study

Cohort study of 3,229 peopleMajor adverse cardiovascular events

Paper

European Stroke Journal6 Oct

Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial

Trial protocolCardiovascular disease

Paper

Lancet1 Oct

Orforglipron matches insulin glargine on cardiovascular safety

Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.

Randomised trial in 2,749 peopleOrforglipron

Paper

Journal of the American Heart Association2 Sep